[HTML][HTML] Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study
M Kishimoto, M Komine, K Kamiya, J Sugai… - Dermatology and …, 2023 - Springer
Introduction This study aimed to retrospectively examine the drug survival of tumor necrosis
factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation …
factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation …
Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study.
M Kishimoto, M Komine, K Kamiya… - Dermatology & …, 2023 - search.ebscohost.com
Introduction: This study aimed to retrospectively examine the drug survival of tumor necrosis
factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation …
factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation …
Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study.
M Kishimoto, M Komine, K Kamiya, J Sugai… - Dermatology and …, 2023 - europepmc.org
Methods This real-world setting study was conducted at a single academic center. We
included patients who were treated with adalimumab (n= 111), certolizumab pegol (n= 12) …
included patients who were treated with adalimumab (n= 111), certolizumab pegol (n= 12) …
Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study
M Kishimoto, M Komine, K Kamiya… - Dermatology and …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction This study aimed to retrospectively examine the drug survival of tumor necrosis
factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation …
factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation …
[HTML][HTML] Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study
M Kishimoto, M Komine, K Kamiya, J Sugai… - Dermatology and …, 2023 - ncbi.nlm.nih.gov
Methods This real-world setting study was conducted at a single academic center. We
included patients who were treated with adalimumab (n= 111), certolizumab pegol (n= 12) …
included patients who were treated with adalimumab (n= 111), certolizumab pegol (n= 12) …
Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study.
M Kishimoto, M Komine, K Kamiya, J Sugai… - Dermatology and …, 2023 - europepmc.org
Methods This real-world setting study was conducted at a single academic center. We
included patients who were treated with adalimumab (n= 111), certolizumab pegol (n= 12) …
included patients who were treated with adalimumab (n= 111), certolizumab pegol (n= 12) …